Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Alterity Therapeutics Ltd
ATHECurrent price
1.2 USD
-0.018 USD (-1.44%)
Last closed
1.22 USD
Company
alteritytherapeutics.com
ISIN
US02155X1063
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
11 015 878 USD
Yield for 12 month
-55.56 %
1Y
3Y
5Y
10Y
15Y
ATHE
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Address: 350 Collins Street, Melbourne, VIC, Australia, 3000
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
7 USDP/E ratio
–Dividend Yield
–Current Year
+1 784 169 USD
Last Year
+1 735 921 USD
Current Quarter
+470 217 USD
Last Quarter
+459 669 USD
Current Year
+1 719 833 USD
Last Year
+1 667 865 USD
Current Quarter
+437 976 USD
Last Quarter
+434 211 USD
Key Figures ATHE
1 year
3 years
5 years
10 years
EBITDA
-19 571 604 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-52.66 %
PEG Ratio
–
Return On Equity TTM
-104.47 %
Wall Street Target Price
7 USD
Revenue TTM
4 019 285 USD
Book Value
0.003 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
38.4 %
Dividend Yield
–
Gross Profit TTM
3 631 266 USD
Earnings per share
-2.08 USD
Diluted Eps TTM
-2.08 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ATHE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATHE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
09.01.2023
Dividend Date
–
Stock Valuation ATHE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
113.9898
Price Sales TTM
2.7408
Enterprise Value EBITDA
0.7546
Price Book MRQ
1.198
Financials ATHE
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ATHE
For 52 weeks
1.01 USD
5.41 USD
50 Day MA
1.32 USD
Shares Short Prior Month
12 539
200 Day MA
1.77 USD
Short Ratio
0.87
Shares Short
9 668
Short Percent
0.11 %
BeatStart